Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.

(2010) A. Di Leo et al.   CANCER RESEARCH

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

(2010) Hester van Cruijsen et al.   EUROPEAN JOURNAL OF CANCER

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

(2009) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A 2009 Update on the Treatment of Patients with Hormone Receptor—Positive Breast Cancer

(2009) Susan J. Cleator et al.   Clinical Breast Cancer

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer

(2009) E. Chen et al.   CLINICAL CANCER RESEARCH

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

(2009) Marlies H.G. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

(2009) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia

(2009) Walter Fiedler et al.   LEUKEMIA RESEARCH

Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000–2007

(2008) Nicholas Wilcken et al.   EUROPEAN JOURNAL OF CANCER

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

(2008) Glenwood Goss et al.   EUROPEAN JOURNAL OF CANCER

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

(2008) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY